Evidence map›Paper›PMID 27676308›Full record

ReviewCurrent biology : CB2016

Gene Flow and Molecular Innovation in Bacteria.

Antonio C Ruzzini, Jon Clardy

Abstract readReview
In one paragraph

Review in Current biology : CB, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Frontiers in microbiology · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Antonio C RuzziniDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Jon ClardyDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: jon_clardy@hms.harvard.edu.

Funding

Metabolomics driven discovery of drug leads from symbiotic bacteriaU19AI109673 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, CURRIE, CAMERON ROBERT · 2014 to 2018
$16.2M
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebratesU19TW009872 · FIC · HARVARD MEDICAL SCHOOL · PI CLARDY, JON, PUPO, MONICA T · 2014 to 2018
$4.4M
Molecule-to-gene approaches to new natural productsR01GM086258 · NIGMS · HARVARD MEDICAL SCHOOL · PI CLARDY, JON · 2008 to 2016
$3.6M
FIC NIH HHS U19 TW009872NIAID NIH HHS U19 AI109673NIGMS NIH HHS R01 GM086258
6 · The paper itself

Abstract

The small molecules produced by environmental bacteria have been mainstays of both chemical and biological research for decades, and some have led to important therapeutic interventions. These small molecules have been shaped by natural selection as they evolved to fulfill changing functional roles in their native environments. This minireview describes some recent systematic studies providing illustrative examples that involve the acquisition and alteration of genetic information for molecular innovation by bacteria in well-defined environments. Two different bacterial genera are featured, Pseudonocardia and Salinispora, and, although the small-molecule repertoires of both have benefited from horizontal gene transfer, Pseudonocardia spp. have relied on plasmid-based tactics while Salinispora spp. have relied on chromosomally integrated genomic islands.

Indexed as

Evolution, MolecularActinobacteriaGene Transfer, HorizontalGenomic IslandsPlasmids

Identifiers

PMID27676308
PMCPMC5076561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.